PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma
(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing ´ s sarcoma at the Connective Tissue Oncology Society ´ s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Bone Cancers | Cancer | Cancer & Oncology | Ewing's Sarcoma | Politics | Sarcomas | Study